Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul;7(13):284.
doi: 10.21037/atm.2019.07.24.

Multisystem late onset Pompe disease (LOPD): an update on clinical aspects

Affiliations
Review

Multisystem late onset Pompe disease (LOPD): an update on clinical aspects

Antonio Toscano et al. Ann Transl Med. 2019 Jul.

Abstract

Pompe disease is classified by age of onset, organ involvement, severity, and rate of progression in two main forms: the first one, infantile onset Pompe disease (IOPD), presents before the age of 12 months with generalized muscle weakness, hypotonia, respiratory distress, and hypertrophic cardiomyopathy as main clinical features. The second form, late onset Pompe disease (LOPD), is characterized by an onset at the age of 12 months to adulthood, hyperCKemia, and limb-girdle and axial muscle weakness, often complicated by respiratory muscles degeneration. In the last 10-15 years, an increasing interest in Pompe disease has led to multiple studies in an effort to clarify the emerging clinical aspects, to find out the best diagnostic tools to identify the disease as early as possible, and to offer new therapeutic options apart from enzyme replacement therapy (ERT). Since 2006, ERT-the first treatment for Pompe disease-has been universally accepted in the majority of countries all over the world. Although for years Pompe disease has been primarily considered a muscle disorder, nowadays it is clear that the involvement of several other organs has changed the cultural approach to this entity which is now viewed as a multisystem disorder. The emerging clinical aspects have greatly expanded the spectrum of the disease manifestations. In fact, central, peripheral, and autonomous nervous systems are often involved; vascular malformations and heart involvement are frequently observed; musculoskeletal and bone changes as well as oro-gastrointestinal and urinary tract alterations have been better defined. A great deal of effort has been made to clarify the clinical aspects of Pompe disease, to raise awareness of the LOPD patients' problems and to improve their quality of life.

Keywords: Late onset Pompe disease presentation (LOPD presentation); Pompe disease; aneurysms; hyperCKemia; myopathy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: A Toscano is a member of Global Pompe Registry committee and has received honoraria for speaking engagements and teaching courses from Sanofi Genzyme. O Musumeci received reimbursements for speaking engagements from Sanofi Genzyme. C Rodolico has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
The LOPD “triangle” of clinical presentations. LOPD, late onset Pompe disease.
Figure 2
Figure 2
LOPD clinical aspects. (A) Unilateral eyelid ptosis in a 64-year-old LOPD female; (B) scapular winging in a 55-year-old LOPD man; (C) positive Gower’s manoeuvre in a 48-year-old LOPD female. LOPD, late onset Pompe disease.
Figure 3
Figure 3
Brain imaging in LOPD. (A) CT-scan showing a vertebral dolichoectasia in a 64-year-old LOPD female; (B) T2 weighted scan showing a lacunar encephalopathy (Fazekas score 2). LOPD, late onset Pompe disease.

References

    1. Müller-Felber W, Horvath R, Gempel K, et al. Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients, Neuromuscul Disord 2007:17:698-706. 10.1016/j.nmd.2007.06.002 - DOI - PubMed
    1. Montagnese F, Barca E, Musumeci O, et al. Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment J Neurol 2015;262:968-78. 10.1007/s00415-015-7664-0 - DOI - PubMed
    1. Musumeci O, la Marca G, Spada M. LOPED study: looking for an early diagnosis in a late-onset Pompe disease high-risk population. J Neurol Neurosurg Psychiatry 2016; 87:5-11. - PubMed
    1. Dasouki M, Jawdat O, Almadhoun O, et al. Pompe disease: literature review and case series. Neurol Clin 2014;32:751. 10.1016/j.ncl.2014.04.010 - DOI - PMC - PubMed
    1. Winkel LP, Hagemans ML, van Doorn PA, et al. The natural course of non-classic Pompe’s disease; a review of 225 published cases. J Neurol 2005;252:875-84. 10.1007/s00415-005-0922-9 - DOI - PubMed